Skip to main content
Contact Us
Subscribe
E-Edition
68°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pfizer
(NY:
PFE
)
27.81
+0.11 (+0.40%)
Official Closing Price
Updated: 7:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pfizer
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
99
100
Next >
ROSEN, A LONGSTANDING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
February 02, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
ROSEN, A LONGSTANDING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
February 02, 2024
WHY: NEW YORK, NY - (NewMediaWire) - February 02, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and...
Via
TheNewswire.com
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
Recent Stock Purchase January 2024
February 02, 2024
With February already underway and the markets on a nice uptrend, I decided to add to some of my lagging existing positions.
Via
Talk Markets
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
February 02, 2024
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Is the Worst Over for Pfizer?
February 01, 2024
Pfizer shares sank 43% last year.
Via
The Motley Fool
Peeling Back The Layers: Exploring Pfizer Through Analyst Insights
January 31, 2024
Via
Benzinga
Pfizer Inc. (NYSE: PFE) Near Top of Volume Charts in Tuesday Trading
January 30, 2024
Via
Investor Brand Network
Exposures
COVID-19
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review
February 02, 2024
The Dow led the major indexes higher. Big techs diverged on results.
Via
Investor's Business Daily
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Bristol Myers Shares Rise On Fourth-Quarter Earnings Beat
February 02, 2024
Bristol Myers earnings came in above expectations, although Opdivo sales were slower than expected. BMY stock gained.
Via
Investor's Business Daily
Million-Dollar Bets: 7 Stocks to Buy Before They Blast Off
February 02, 2024
Seven stocks set to soar: Foundries to pharma, finance's evolution, and digital transformation—unlock million-dollar opportunities.
Via
InvestorPlace
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
February 02, 2024
From
Genmab A/S
Via
Business Wire
Pfizer Surprises With Profit But Revolutionizing Cancer Treatment Is Its Best Chance Of Getting Back In The Saddle
February 01, 2024
On Tuesday, Pfizer Inc (NYSE: PFE) reported mixed results for its fourth quarter. Last year, Pfizer has responded to concerns related to its COVID-19 products being the rearview mirror with a...
Via
Benzinga
Exposures
COVID-19
Pfizer’s 2024 Comeback: A Dividend Gem in the Pharma Market
February 01, 2024
Pfizer is in Wall Street's doghouse, but don't despair. At its current price, value seekers ought to relish the opportunity to buy PFE stock.
Via
InvestorPlace
What's Going On With Pfizer Stock Today?
February 01, 2024
Pfizer stock update: Q4 earnings beat expectations with adjusted EPS of $0.10, while FY2023 shows a 72% YoY decline. Explore 2024 R&D plans and recent program discontinuations.
Via
Benzinga
Topics
Earnings
Exposures
Financial
Biotech And Medtech Portfolio Notes On A Fed Day
January 31, 2024
The Fed held rates keeping their future options flexible with no expectations for future cuts. The market did not like it and sold off with the Russell 2000 down 2.45% and the NASDAQ down 2.23%
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
3 Once-in-a-Lifetime Penny Stocks With Unprecedented Surge Potential
January 31, 2024
Is your portfolio is in dire need of making new all-time highs? A new economic cycle is to send these penny stocks with potential up.
Via
InvestorPlace
Listen to Wall Street and Buy These 3 Stocks Now
January 31, 2024
With a Wall Street recommended stock, you have the comfort of expert analysis along with a possible market-moving influence.
Via
InvestorPlace
3 Standout Stocks That Crushed Q4 Earnings Estimates
January 31, 2024
These three stocks crushing Q4 earnings are on the rise after the companies behind them closed the year with a bang.
Via
InvestorPlace
Novavax Layoffs 2024: What to Know About the Latest NVAX Job Cuts
January 31, 2024
The Novavax layoffs are coming for 12% of the company's global workforce. However, NVAX stock itself could shock the market.
Via
InvestorPlace
Topics
Workforce
Exposures
Layoff
Take Your Ozempic: Why Late Entry Of Rival Weight-Loss Drugs Won't Floor Novo, Eli Shares
January 31, 2024
Eli Lilly to report strong Q4 earnings thanks to successful diabetes treatments, while rivals like Novo Nordisk and Pfizer are also vying for a share of the weight-loss market.
Via
Benzinga
A New COVID-19 Variant Is Rapidly Spreading Around The Globe, Other Pandemic Threats Exist – What Are The Choices For Treatment?
January 31, 2024
Colds, flu and RSV aren't the only viral illnesses people have to worry about this winter. A new variant of COVID-19 is rapidly spreading, reminding the world of just how dangerous this virus is.
Via
Benzinga
Exposures
COVID-19
Best Income Stocks 2024
January 31, 2024
The pros and cons of 7 companies in 4 different sectors.
Via
Talk Markets
Pfizer (PFE) Q4 2023 Earnings Call Transcript
January 30, 2024
PFE earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Why Pfizer Stock Was Jumping Today, but Then Gave Up Its Gains
January 30, 2024
The drugmaker's Q4 results were better than many expected, but still not good enough to spark a sustained rally.
Via
The Motley Fool
Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60%
January 30, 2024
Explore the impact of the U.S. government's proposal on pharmaceuticals! Learn about Medicare's negotiation power, potential price cuts, and industry reactions.
Via
Benzinga
US Stocks Edge Lower; Pfizer Reports Surprise Profit
January 30, 2024
U.S. stocks traded slightly lower this morning on Tuesday. Following the market opening Tuesday, the Dow traded down 0.04% to 38,316.43 while the NASDAQ fell 0.12% to 15,608.59. The S&P 500 also fell,...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Pfizer Q4 Results: $14.25B In Revenue And EPS Of $0.1, Exceeding Forecasts
January 30, 2024
Pfizer reports Q4 2023 with strong financial results, achieving $14.25 billion in revenue and an EPS of $0.1.
Via
Talk Markets
Pfizer Reports Surprise Profit Despite Continued Covid Sales Downfall
January 30, 2024
The company also reiterated its guidance for the full year.
Via
Investor's Business Daily
Exposures
COVID-19
Pfizer Surprises With Q4 Profit Despite Muted COVID Products Demand, Sticks To 2024 Guidance
January 30, 2024
Pfizer's Q4 2023 financial report: adjusted EPS beats estimates at $0.10, FY2023 EPS down 72%, Q4 sales decline 41% to $14.25B. CEO's positive outlook and reaffirmed 2024 guidance.
Via
Benzinga
Exposures
COVID-19
US Stocks Hold Steady Ahead Of Microsoft, Alphabet Earnings: Analyst Warns Of 'Big Air Pocket' In Pivotal Trading Week
January 30, 2024
After a record run, U.S. stocks could pause for a breather ahead of the tech earnings deluge that is expected to hit the Street this week.
Via
Benzinga
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.